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Summary. During an oral glucose tolerance test 
(OGTT) glucose and insulin levels were measured in 
26 patients with prolactin-producing pituitary 
tumours without growth hormone excess. Basal glu-
cose and insulin levels did not differ from the values of 
an age-matched control group. After glucose load the 
hyperprolactinaemic patients showed a decrease in 
glucose tolerance and a hyperinsulinaemia. Bromo-
criptine (CB 154), which suppressed PRL, improved 
glucose tolerance and decreased insulin towards nor-
mal in a second OGTT. - Human PRL or CB 154 had 
no significant influence on insulin release due to glu-
cose in the perfused rat pancreas. - These findings 
suggest a diabetogenic effect of PRL. CB 154 might be 
a useful drug in improving glucose utilization in hor-
mone-active pituitary tumours. 
Key words: Prolactin, insulin release, glucose toler-
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Acute administration of ovine prolactin (PRL) has 
been shown to influence glucose metabolism in ani-
mals [1, 2], to impair glucose tolerance in hypopitui-
tary dwarfs and in hypophysectomized juvenile-type 
diabetics [3], and to stimulate lipid metabolism [4]. In 
order to study the long term effects of endogenous 
PRL on glucose tolerance and glucose-induced insulin 
secretion, patients with hyperprolactinaemia were in-
vestigated. In vitro experiments with the isolated per-
fused rat pancreas were undertaken to elucidate the 
direct effect of hPRL on insulin release. 
* Presented in part at the 11th Annual Meeting of the European 
Association for the Study of Diabetes (EASD), Munich, September 
4-6, 1975, and published in abstract form in Diabetologia 11, 357 
(1975) 
Material aud Methods 
a. In vivo-Study 
Fifteen female and 11 male patients with hyperprolac-
tinaemia were studied (Tab. 1). Twenty-four patients 
had a pituitary tumour, one had a craniopharyngioma 
and one had anormal sella turcica. A galactorrhoea-
amenorrhoea syndrome was observed in 9 women. 
The average body weight was 13 ± 4 % above the ideal 
body weight and the average age was 34 ± 2 years 
(mean ± SEM). None of the patients had elevated 
plasma growth hormone concentrations. Eighteen pa-
tients had blunted hGH-secretion after insulin-in-
duced hypoglycaemia. In six subjects TSH levels be-
fore and after TRH stimulation were below the lower 
limit of detection; six patients showed TSH values 
which were subnormal and two suffered from primary 
hypothyroidism. Thirteen had secondary hypogonad-
ism, eleven had a latent or manifest secondary adrenal 
insufficiency and three had diabetes insipidus. The 
mean basal PRL level (x ± SEM) measured by 
radioimmunoassay [5] was 2422 ± 800 ng/ml ranging 
from 47 to 18 860 ng/ml. Our normal range for men is 
8.5 to 25 ng/ml and for women up to 37.5 ng/ml. 
Fourteen patients were on appropriate hormone re-
placement therapy at the time of the study. 
Hypothyroidism was treated in all cases except two 
(Tab. 1) in order to avoid effects of low thyroid hor-
mone levels on glucose tolerance. 
Fifteen patients (nine females and six males) were 
treated with bromocriptine (CB 154) 3 to 10 mg daily 
for at least one week and on average for five weeks 
(upper part of Tab.1). 
Plasma prolactin, glucose tolerance and insulin 
release were determined again under treatment. After 
an overnight fast oral glucose tolerance tests (100 g) 
were performed between 8 and 9 a. m. Blood sampIes 
were taken just before (0 min) and 30, 60, 120 and 
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Table 1. Summary of the c1inical data of the hyperprolactinaemic patients. 1) Mean basal hPRL levels ± SEM. Number in parenthesis = 
number of determinations on different occasions. 2) Cortisol: + = basal cortisol (> 4 [.lg/100 ml) and AClli-stimulated (25 I. U.) cortisol 
(> 23 [.lg/100 ml) and adequate increase of cortisol on insulin-induced hypoglycaemia. (+) = no significant cortisol increase during 
insulin-induced hypoglycaemia. 3) Luteinizing hormone (LH): + = normal before and after 25 [.lg LH-RH i. v. ( Il LH > 2,5 ng/ml). 4) 
Growth hormone (hGH): + = normal basal « 5 ng/ml) and stimulated levels (> 40% increment above baseline) following insulin-induced 
hypoglycaemia or arginine i. v. 5) Thyrotropin (TSH): + = normal (Il TSH > 2.6 [.lU/mi) before and after 200 [.lg TRH i. v. (+) = 
insufficient TSH response after TRH. 6) Diabetes insipidus was diagnosed by serum (> 301 mosm/kg) and urine ( < 700 mosm/kg) osmolality 
after a thirst period up to 18 hours. 7) P. A = Pituitary adenoma (X-ray) G. A S. = Galactorrhea-Amenorrhea-Syndrome. For further 
analytical details (21) 
Patient Sex Age % Basal Cortisol LH hGHTSH Diab. Diagnosis Replacement 
ideal hPRL insipi- Therapy 
body ng/ml ' dus 
weight 1) 2) 3) 4) 5) 6) 7) 
AW. M 32 +47 + + P.A 
RA M 52 +6 + + (+) P.A T4 
G.M. M 39 +19 + (+) P.A testosterone, T4 
AS. M 29 +17 + P.A cortisol 
H.Q. M 34 +13 + P.A cortisol, T4, ADH, testosterone 
H.G. M 30 +10 + P.A cortisol, T4, TegretalR, testosterone 
C.H. F 28 -16 P.A.+G.AS. 
E.F. F 35 +11 + (+) + P.A+G.AS. 
J.H. F 26 -5 + + + + P.A 
E.M. F 25 +7 + + + + P.A+G.AS. 
C.W. F 19 -3 + + (+) P.A+G.AS. 
B.P. F 24 -2 See Table 2 + + + + P.A+G.AS. 
RM. F 40 +21 + + P. A + prim. hypo- cortisol, T4, TegretalR 
thyroidism 
S.L. F 24 +10 + + + + P.A+G.AS. 
M.O. F 38 +19 + (+) P.A T4,oestrogens 
M.H. M 33 +11 452± 44 (8) (+) + P.A 
AH. M 50 +51 4221±161 (9) + + + P.A T4 
K.W. M 50 +30 47± 3 (3) + P. A + prim. hypo- cortisol, T4, 'testosterone 
thyroidism 
B.P. M 22 +4 2524±947 (4) + + P.A cortisol 
J.R M 51 +32 1412± 18 (3) P.A cortisol, T 3' testosterone 
I. S. F 21 -14 384 (1) + + + (+) P.A+G.AS. 
RW. F 44 -4 140 (1) + + + amenorrhea, 
no tumour 
AS. F 26 -20 113± 10(6) + + (+) P.A+G.AS. 
B.T. F 32 ±O 298± 74 (2) + + + P.A cortisol 
c.K. F 29 +32 63 (1) (+) + (+ ) craniopharyn- cortisol, T4 
gioma 
RW. F 38 +61 3229± 78 (7) + (+) + P.A. +G.AS. T4 
180 min after glucose loading. Serum insulin was de- earlier [8]. Human PRL was purified by column 
termined by radioimmunoassay [6]. PRL or bromo- chromatography [9] from serum of one of OUf patients 
criptine did not interfere with the insulin assay. Blood with an extreme hyperprolactinaemia (H. Q. in Tables 
glucose was measured by the hexokinase method [7]. 1 and 2), and was added to the perfusion medium at a 
The results from the hyperprolactinaemic patients concentration of 50 and 250 ng/ml. Bromocriptine 
were compared with a control group of ten males and was perfused at 20, 100 and 200 !!g/lOO ml. 
six females, with an average age of 36 ± 3 years (mean 
± SEM) and an average body weight of 99 ± 2% of Results ideal body weight. The data were analyzed for statisti-
cal significance using the paired Wilcoxon test. 
a. In vivo-Study 
b. In vitro-Study Basal glucose and serum insulin values in hyper-prolactinaemic patients and normal subjects did not 
For the in vitro experiments, overnight fasted male differ significantly. After a glucose load the patients 
Sprague-Dawley rats were used as pancreas donors. with prolactin excess showed a markedly reduced glu-
Pancreatic perfusions were carried out as published cose tolerance and an enhanced and delayed insulin 
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Fig.l. Left side: Blood glucose and serum insulin values (x ± SEM) in normal subjects and hyperprolactinaemic patients before and after oral 
glucose loading. Right side: Blood glucose and serum insulin values (x ± SEM) in patients with hyperprolactinaemia before and after CB 154 
during an oral glucose tolerance test (OGTI) 
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Fig. 2. Insulinogenic indices (mean ± SEM) for normal subjects, all 
hyperprolactinaemic patients and those patients who were ex-
amined before and after CB 154 treatment. The insulinogenic index 
was ca1culated using the sum of the increments of insulin and 
glucose responses to the OGTT 
response (Fig. 1, left side). This is in agreement with 
recent findings from Tourniaire et aI. [10]. Fifteen of 
the hyperprolactinaemic patients were treated with 
CB 154; as shown in Table 2 the PRL levels were 
suppressed by 86 ± 3%. At the same time glucose 
tolerance was improved and glucose-induced insulin 
release reached almost normal values (Fig.1, right 
side). 
Calculating the insulinogenic index, a significant 
increase was observed in the hyperprolactinaemic pa-
tients when compared to the control group (Fig.2). 
Comparison of the insulinogenic index in patients be-
fore and after CB 154 revealed a c1ear decrease under 
treatment. The value obtained did not differ from that 
of the control subjects (Fig.2). 
b. In vitro-Study 
To determine whether the PRL and CB 154 effects 
observed in vivo were mediated through a direct ac-
tion of these substances on the pancreatic B-cell, in 
vitro experiments with the isolated perfused rat pan-
creas were undertaken during glucose stimulation. As 
shown in Figure 3 the glucose-stimulated insulin re-
lease in the perfused pancreas slightly decreased after 
addition of hPRL (top panel) or CB 154 (bottom 
panel). However, the suppressive effects of these sub-
stances were not statistically significant. 
Discussion 
The disturbances of glucose tolerance and glucose-in-
duced insulin release observed in the hyperprolac-
tinaemic patients did not correlate with any of the 
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Fig. 3. Insulin secretory profiled 
induced by sequential perfusion of 
glucose and glucose plus hPRL (top) 
or glucose plus CB 154 (bottom) at 
concentrations indicated in the 
graphs, Mean values ± SEM for three 
animals under each condition 
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Table 2. Basal prolactin levels (x ± SEM) in 15 patients with 
hyperprolactinaemia before and under CB 154 treatment. Number 
of determinations on different occasions in parenthesis. For c1inical 
details see Table 1 (upper part) 
Patient hPRL before hPRLunder % suppression 
CB 154 treatment CB 154 treatment ofhPRL by 
CB 154 
ng/ml ng/ml treatment 
W.A. 638 ± 22 (8) 13± 2 (8) 98 
RA. 1299 ± 136 (5) 88 (1) 93 
G.M. 4411 ± 303 (11) 1146 ± 165 (3) 74 
A.S. 5458 ± 532 (10) 236 (1) 96 
H.Q. 18860 ± 867 (8) 233 ± 29 (9) 99 
H.G. 10218 ± 193 (2) 325 ± 27 (5) 97 
C.H. 2717± 59 (6) 581 (1) 79 
E.P. 119± 8 (6) 24 (1) 80 
I.H. 2037 ± 25 (4) 176 ± 24 (5) 91 
E.M. 125 ± 9 (4) 58 ± 6 (6) 54 
C.W. 364 ± 19 (3) 21 ± 5 (3) 94 
B.P. 140 ± 4 (8) 11± 2 (5) 92 
RM. 2674 (1) 815 (1) 70 
S.L. 917 ± 39 (8) 166 ± 7 (4) 82 
M.O. 99 (1) 4 (1) 96 
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Fig. 4. Relation between the deviation from ideal body weight and 
the integrated insulin output in the patients with hyperprolac-
tinaemia (n=26). r = correlation coefficient 
endocrine deficiencies seen in oUf patients (Tab. 1). 
There was also no direct relation between body weight 
and integrated insulin release in the hyperprolac-
tinaemic patients (Fig.4). Since the body weight of 
our patients did not change during CB 154 treatment, 
the possibility that the improvement of the glucose 
metabolism and hyperinsulinaemia could be attri-
buted to changes in body weight could be mIed out. 
No sex difference could be observed. 
Although there was no correlation between the 
absolute PRL levels and the degree of metabolic alter-
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ations, we concluded, especiaIly in view of the CB 154 
data, that the hyperprolactinaemia was responsible 
for our findings. 
The improvement in glucose tolerance tended to 
be more marked in those patients who showed a 
greater suppression of their prolactin levels with 
bromocriptine. 
The lack of correlation between the severity of 
PRL excess and the degree of glucose imbalance and 
hyperinsulinaemia might reflect discrepancies be-
tween the immunoreactivity of PRL and its biological 
activity. The existence of circulating immunoreactive 
hormones with reduced biological activity has been 
amply demonstrated, especiaIly for hGH [11]. 
The mechanisms involved in prolactin-induced 
changes in glucose homoeostasis and insulin release 
are unknown. In animal studies some results are com-
patible with the findings in OUf patients; others are 
not. 
Daily injections of high doses of PRL (1 mg/kg) in 
hypophysectomized dogs caused a rise in basal blood 
sugar and a diminished sensitivity to injected insulin; 
the glucose tolerance, however, was not impaired 
[12]. In hypophysectomized and adrenalectomized 
dogs or in partially depancreatized animals ovine PRL 
produced overt diabetes [13]. However, in arecent 
study Renauld et al. [14] were not able to demonstrate 
any significant "anti-insulin" effects of chronic PRL 
administration in the normal dog. A similar finding 
was made in hypophysectomized rats treated with 
ovine PRL [15]. 
The significant alterations in glucose metabolism 
after long-term endogenous hyperprolactinaemia 
seen in OUf investigation might be explained by in-
creased gluconeogenesis in the liver, enhanced 
peripheral resistance to insulin and/or altered re-
sponse of the pancreatic B-ceIl to glucose loading. 
Rathgeb et al. [2] showed increased hepatic glucose 
output in normal dogs treated with PRL. In their 
study, however, plasma glucose was virtually un-
changed due to a concomitant stimulation of glucose 
uptake by peripheral tissues under PRL treatment. 
Plasma insulin levels were not altered. Therefore this 
mechanism seems not to be the exclusive one in hyper-
prolactinaemic patients. 
Since PRL induces a rise in plasma free fatty acids 
in the dog [16] as weIl as in man [4] the impairment of 
the glucose tolerance seen in our patients might be due 
to the known inhibitory effect of elevated free fatty 
acids on peripheral glucose uptake. This hypothesis 
remains to be tested. 
The possibility that the hyperinsulinaemia seen in 
OUf patients is due to a direct effect of PRL on the 
B-cell remains to be confirmed especiaIly since Rath-
geb et al. [2] did not find anychangesin plasma insulin 
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during PRL administration. Our in vitro experiments 
suggest that a short exposure of the pancreas to pro-
lactin did not change the beta cell sensitivity to glu-
cose. They do not, however, rule out an effect of 
prolonged exposure to high PRL levels on the pan-
creas. Different effects occuring with short- and long 
term administration of growth hormone, a polypep-
tide chemically and biologically closely related to 
PRL, have been reported [17, 18]. 
The striking reduction of glucose-induced insulin 
release in hyperprolactinaemic patients treated with 
CB 154 is probably due to a suppression of the PRL 
levels and not due to an influence of CB 154 on insulin 
release at the pancreatic level. This view is supported 
by our perfusion experiments, in which CB 154 in 
pharmacological doses had no significant influence on 
glucose-stimulated insulin secretion. Treatment of 
healthy volunteers (n =5) with CB 154 (8 mg dailyfor 
7 days) had no influence on glucose tolerance and 
insulin release. This is in agreement with data from del 
Pozo et al. [19]. 
The present findings might be of therapeutic im-
portance, since suppression of the release of dia-
betogenic hormones like hOR and hPRL with 
bromocriptine in endocrine disturbances like acrome-
galy [20], hyperprolactinaemia or juvenile-type dia-
betes mellitus (Landgraf et al., unpublished observa-
tion) might improve the metabolic disturbances seen 
in these patients. 
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